Author

C. C. Collins

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Research Focus:drug response / drug discovery· 3 Research Focus:gene regulatory network inference· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2

Frequent Co-Authors

Y.-Y. Lin· 4 shared H. Xue· 3 shared S. Anderson· 3 shared S. Volik· 3 shared Y. Wang· 3 shared A. Haegert· 2 shared B. McConeghy· 2 shared D. Lin· 2 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Y.-Y. Lin

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Deciphering the Transcription Factor Landscape in Neuroendocrine Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation

Y. Wang, H. Xue, X. Zhu, D. Lin, X. Dong, Z. Chen, J. Chen, M. Shi, Y. Ni, J. Cao, R. Wu, N. Kang, X. Pang, F. Crea, Y.-Y. Lin, , Y. Wang

This study identifies lineage-specific transcription factor profiles in prostate cancer progression, revealing dynamic shifts during NE transdifferentiation and proposing a three-phase model.

bioRxiv · Apr 27, 2024Cancer Biology

5'-S-(3-aminophenyl)-5'-thioadenosine, a novel chemoprotective agent for reducing toxic side effects of fluorouracil in treatment of MTAP-deficient cancers

S. Zhang, H. Xue, N. K. Y. Wong, T. Doerksen, F. Ban, S. Anderson, S. Volik, Y.-Y. Lin, Z. Dai, I. Bratanovic, H. Cheng, C. C. Collins, A. Cherkasov, J. Wulff, Y. Wang

This paper identifies m-APTA, an MTA analogue that reduces NBA toxicity without hypothermia, improving safety for MTAP-deficient cancer treatment.

bioRxiv · Apr 17, 2024Cancer Biology

A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma

L. Ramos, S. Truong, B. Zhai, J. Joshi, F. Ghaidi, M. M. Lizardo, T. Shyp, H. Adomat, S. LeBihan, C. C. Collins, J. Bacha, D. Brown, J. Langlands, W. Shen, N. Lallous, , M. Daugaard

This paper develops a dual PARP and HDAC inhibitor, kt-3283, showing enhanced cytotoxicity and efficacy in Ewing sarcoma models compared to single-agent inhibitors.

bioRxiv · Nov 10, 2022 · PreprintCancer Biology

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian Carcinoma

R. Shrestha, M. L. Fernandez, A. Dawson, J. Hoenisch, S. Volik, Y.-Y. Lin, S. Anderson, H. Kim, A. Haegert, S. Colborne, B. McConeghy, R. H. Bell, S. Brahmbhatt, G. E. DiMattia, S. Le Bihan, , M. S. Carey

This study uses multiomics analysis of LGSOC cell lines to identify therapeutic vulnerabilities and biomarkers for MEK inhibitor efficacy.

bioRxiv · Jun 18, 2020 · PreprintCancer Biology

BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma

R. Shrestha, N. Nabavi, Y.-Y. Lin, F. Mo, S. Anderson, S. Volik, H. H. Adomat, D. Lin, H. Xue, X. Dong, R. Shukin, R. H. Bell, B. McConeghy, A. Haegert, S. Brahmbhatt, , C. C. Collins

The paper identifies BAP1 loss as a marker for a distinct immunogenic PeM subtype, suggesting potential therapeutic targets like immune checkpoint inhibitors.

bioRxiv · Dec 13, 2018Cancer Biology